Anthony J. Hickey

Technology Advancement and Commercialization, RTI International

Research Area

MedicineUnit 1

Biography

Anthony J. Hickey has not added Biography.
If you are Anthony J. Hickey and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title	2017
Publication title	2023

Other Publications

Article	Year
Back to the future: inhaled drug products. Journal of pharmaceutical sciences\| PubMed ID: 23381932	2013
New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation. PloS one\| PubMed ID: 24489969	2014
Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Advanced drug delivery reviews\| PubMed ID: 24819218	2014
Controlled delivery of inhaled therapeutic agents. Journal of controlled release : official journal of the Controlled Release Society\| PubMed ID: 24907604	2014
Scale of health: indices of safety and efficacy in the evolving environment of large biological datasets. Pharmaceutical research\| PubMed ID: 24919930	2014
The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. Journal of microencapsulation\| PubMed ID: 25090595	2014
Targeting inhaled therapy beyond the lungs. Respiration; international review of thoracic diseases\| PubMed ID: 25277464	2014
In vitro dry powder inhaler formulation performance considerations. Journal of controlled release : official journal of the Controlled Release Society\| PubMed ID: 25497311	2015
Inhaled drug treatment for tuberculosis: Past progress and future prospects. Journal of controlled release : official journal of the Controlled Release Society\| PubMed ID: 26596254	2016
Real-Time Investigation of Tuberculosis Transmission: Developing the Respiratory Aerosol Sampling Chamber (RASC). PloS one\| PubMed ID: 26807816	2016
A dry powder combination of pyrazinoic acid and its n-propyl ester for aerosol administration to animals. International journal of pharmaceutics\| PubMed ID: 27130363	2016
Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis. Pharmaceutical research\| PubMed ID: 27351427	2016
Nanomaterial Drug Products: Manufacturing and Analytical Perspectives. The AAPS journal\| PubMed ID: 27822601	2017
Systems biology for organotypic cell cultures. ALTEX\| PubMed ID: 27846345	2016
Influence of Formulation Factors on the Aerosol Performance of Suspension and Solution Metered Dose Inhalers: A Systematic Approach. The AAPS journal\| PubMed ID: 28593514	2017
Density and Shape Factor Terms in Stokes' Equation for Aerodynamic Behavior of Aerosols. Journal of pharmaceutical sciences\| PubMed ID: 29154770	2018
Reproducibility, sharing and progress in nanomaterial databases. Nature nanotechnology\| PubMed ID: 29209007	2017
Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respiratory medicine\| PubMed ID: 29413503	2018
Effects of Formulation Variables on Lung Dosimetry of Albuterol Sulfate Suspension and Beclomethasone Dipropionate Solution Metered Dose Inhalers. AAPS PharmSciTech\| PubMed ID: 29858973	2018
Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. International journal of pharmaceutics\| PubMed ID: 30077761	2018
Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis. PloS one\| PubMed ID: 30261007	2018
Exploiting machine learning for end-to-end drug discovery and development. Nature materials\| PubMed ID: 31000803	2019
A Spray-Dried Combination of Capreomycin and CPZEN-45 for Inhaled Tuberculosis Therapy. Journal of pharmaceutical sciences\| PubMed ID: 31152746	2019
Development and Characterization of a Dry Powder Formulation for Anti-Tuberculosis Drug Spectinamide 1599. Pharmaceutical research\| PubMed ID: 31321552	2019
Sterilization of Mycobacterium tuberculosis infected samples using methanol preserves anti-tuberculosis drugs for subsequent pharmacological testing studies. Tuberculosis (Edinburgh, Scotland)\| PubMed ID: 31378268	2019
Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs. Pharmaceutical research\| PubMed ID: 31650321	2019
Emerging trends in inhaled drug delivery. Advanced drug delivery reviews\| PubMed ID: 32663488	2020
Synergistic drug combinations and machine learning for drug repurposing in chordoma. Scientific reports\| PubMed ID: 32737414	2020
Designing inhalable metal organic frameworks for pulmonary tuberculosis treatment and theragnostics via spray drying. Chemical communications (Cambridge, England)\| PubMed ID: 33025961	2020
A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. CPT: pharmacometrics & systems pharmacology\| PubMed ID: 33296558	2021
User-life of ICS/LABA inhaler devices should be considered when prescribed as relievers. The European respiratory journal\| PubMed ID: 33446577	2021
Microfluidic and Organ-on-a-Chip Approaches to Investigate Cellular and Microenvironmental Contributions to Cardiovascular Function and Pathology. Frontiers in bioengineering and biotechnology\| PubMed ID: 33614613	2021
Inhaled antibodies: Quality and performance considerations. Human vaccines & immunotherapeutics\| PubMed ID: 34191682	2022
A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease. Expert opinion on drug delivery\| PubMed ID: 34311641	2021
Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis. ACS infectious diseases\| PubMed ID: 34546724	2021
In vitro-in vivo correlation of pharmaceutical aerosols. Advanced drug delivery reviews\| PubMed ID: 34710531	2021
COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea. Scientific reports\| PubMed ID: 35351914	2022
Nanoformulated Remdesivir with Extremely Low Content of Poly(2-oxazoline)-Based Stabilizer for Aerosol Treatment of COVID-19. Macromolecular bioscience\| PubMed ID: 35526106	2022
Efficacy of inhaled CPZEN-45 in treating tuberculosis in the guinea pig. Tuberculosis (Edinburgh, Scotland)\| PubMed ID: 35588549	2022
Optimization and Scale Up of Spray Dried CPZEN-45 Aerosol Powders for Inhaled Tuberculosis Treatment. Pharmaceutical research\| PubMed ID: 36114362	2022
Multiple approaches to repurposing drugs for neuroblastoma. Bioorganic & medicinal chemistry\| PubMed ID: 36208544	2022
Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19. Bioengineering & translational medicine\| PubMed ID: 36248234	2022
Spray dried tigecycline dry powder aerosols for the treatment of Nontuberculous mycobacterial pulmonary infections. Tuberculosis (Edinburgh, Scotland)\| PubMed ID: 36716525	2023
Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes. Tuberculosis (Edinburgh, Scotland)\| PubMed ID: 37120915	2023
Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration. Pharmaceuticals (Basel, Switzerland)\| PubMed ID: 37242512	2023
Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics. Pharmaceutics\| PubMed ID: 37376207	2023
Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations. Molecular pharmaceutics\| PubMed ID: 37590399	2023